Syndax Pharmaceuticals Inc — fact timeline

Syndax Pharmaceuticals Inc issued $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 of convertible note to certain investors for approximately $243.0 million net proceeds.

“(and the foregoing description is qualified in its entirety by reference to such documents). Proceeds The Company’s net proceeds from the Private Placement were approximately $243.0 million, after deducting the placement agent’s fees and Private Placement expenses payable by the Company. The Company expects to use the net proceeds from the Private Placement for”

Syndax Pharmaceuticals Inc incurred convertible notes of $250.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 2.25% maturing due 2031.

“issued $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031”

Syndax Pharmaceuticals Inc shareholders approved Approval of the 2026 ESPP at the 2026-06-10 meeting.

“For Against Abstain Broker Non-Votes 58,661,941 74,047 26,875 8,034,588”

Syndax Pharmaceuticals Inc shareholders approved Approval of the 2026 Plan at the 2026-06-10 meeting.

“For Against Abstain Broker Non-Votes 33,333,263 25,392,051 37,549 8,034,588”

Syndax Pharmaceuticals Inc shareholders approved Ratification of selection of independent registered public accounting firm at the 2026-06-10 meeting.

“For Against Abstain Broker Non-Votes 66,603,912 162,947 30,592 —”

Syndax Pharmaceuticals Inc shareholders approved Advisory vote on executive compensation at the 2026-06-10 meeting.

“For Against Abstain Broker Non-Votes 55,688,039 2,985,350 89,474 8,034,588”

Syndax Pharmaceuticals Inc shareholders approved Election of directors at the 2026-06-10 meeting.

“Pierre Legault 37,294,888 21,467,975 8,034,588 Michael A. Metzger 58,113,110 649,753 8,034,588”

Syndax Pharmaceuticals Inc issued convertible note to certain investors for $250.0 million aggregate principal amount.

“the Company will issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031”

Syndax Pharmaceuticals Inc entered into Indenture with U.S. Bank Trust Company, National Association valued at $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (effective 2026-06-03).

“On June 3, 2026, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into privately negotiated subscription agreements (the “ Subscription Agreements ”) with certain investors, pursuant to which the Company will issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the “ Notes ”).”

Syndax Pharmaceuticals Inc reported first quarter ended March 31, 2026 results: revenue Total revenue of $64.9 million.

“Syndax Reports First Quarter 2026 Financial Results and Provides Business Update • Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – • Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26”

Syndax Pharmaceuticals Inc: Amended bylaws to provide that shares of capital stock shall be issued solely in uncertificated form starting December 18, 2025, with existing certificated shares remaining in certificated form until surrendered (effective 2025-12-18).

“On December 18, 2025, the Board of Directors of Syndax Pharmaceuticals Inc. (the “ Company ”) approved amendments to the Amended and Restated Bylaws (the “ Bylaws ”) of the Company, effective on such date. The amendments to the Bylaws provide that, beginning on December 18, 2025, shares of the Company’s capital stock shall be issued solely in uncertificated form; however, shares represented by a certificate issued prior to December 18, 2025 shall remain in certificated form until such certificate is surrendered to the Company.”

Neil Gallagher resigned as President, Head of Research and Development at Syndax Pharmaceuticals Inc.

“Neil Gallagher, M.D. Ph.D, President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development.”

Nicholas A.J. Botwood was appointed as Head of Research and Development, Chief Medical Officer at Syndax Pharmaceuticals Inc.

“Nicholas A.J. Botwood, BSC (HONS), MB BS, MFPM, FRCP, will join the Company as Head of Research and Development, Chief Medical Officer, effective May 12, 2025.”

Syndax Pharmaceuticals Inc shareholders approved Ratification of selection of independent registered public accounting firm at the 2024-05-15 meeting.

“Proposal 3 : Ratification of selection of independent registered public accounting firm: For Against Abstain Broker Non-Votes 65,371,337 253,270 21,499 —”

Syndax Pharmaceuticals Inc shareholders approved Advisory vote on executive compensation at the 2024-05-15 meeting.

“Proposal 2 : Advisory vote on executive compensation: For Against Abstain Broker Non-Votes 46,228,421 16,304,796 80,119 3,032,770”

Syndax Pharmaceuticals Inc shareholders approved Election of directors at the 2024-05-15 meeting.

“Proposal 1 : Election of directors: Nominee For Withheld Broker Non-Votes Martin H. Huber, M.D. 61,876,711 736,625 3,032,770”

Briggs W. Morrison resigned as Director at Syndax Pharmaceuticals Inc.

“On May 14, 2024, Briggs W. Morrison, M.D. advised the Board that he will resign from his position as a Class III member of our Board effective immediately.”

Aleksandra Rizo was elected as Director at Syndax Pharmaceuticals Inc.

“On May 15, 2024, the Board of Directors (the “ Board ”) of Syndax Pharmaceuticals, Inc. (the “ Company ”), unanimously voted to elect Aleksandra Rizo, M.D., Ph.D. to the Board, effectively immediately”

Syndax Pharmaceuticals Inc reported the quarter ended March 31, 2024 results: net income net loss attributable to common stockholders of $72.4 million, EPS $0.85 per share.

“Syndax reported a net loss attributable to common stockholders of $72.4 million, or $0.85 per share, compared to a net loss attributable to common stockholders of $41.1 million, or $0.59 per share, for the comparable prior year period”

Steven Closter was appointed as Chief Commercial Officer at Syndax Pharmaceuticals Inc.

“On March 18, 2024, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Steven Closter will join the Company as Chief Commercial Officer, effective immediately.”

Steve Sabus resigned as Chief Commercial Officer at Syndax Pharmaceuticals Inc.

“On March 15, 2024, Steve Sabus, the previous Chief Commercial Officer of the Company, notified the Company of his voluntary resignation from his position due to personal reasons.”

Syndax Pharmaceuticals Inc reported financial results for the fourth quarter and full year ended December 31, 2023.

“On February 27, 2024, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.”

Syndax Pharmaceuticals Inc entered into Underwriting Agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters valued at approximately $200.0 million (effective 2023-12-14).

“On December 14, 2023, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters (collectively, the “ Underwriters ”), relating to the issuance and sale of 10,810,810 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), at a price to the public of $18.50 per share (the “ Offering ”).”

Syndax Pharmaceuticals Inc reported financial results for the quarter ended September 30, 2023.

“On November 2, 2023, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2023.”

Syndax Pharmaceuticals Inc reported the quarter ended June 30, 2023 results: net income net loss attributable to common stockholders of $44.6 million, or $0.64 per share, EPS $0.64 per share. Guidance reaffirmed.

“For the three months ended June 30, 2023, Syndax reported a net loss attributable to common stockholders of $44.6 million, or $0.64 per share, compared to a net loss attributable to common stockholders of $37.6 million, or $0.62 per share, for the comparable prior year period.”

Syndax Pharmaceuticals Inc terminated Prior Sales Agreement with Cowen and Company, LLC (effective 2023-03-26).

“On March 26, 2023, Syndax delivered written notice to TD Cowen to terminate the Prior Sales Agreement pursuant to Section 11(b) thereof.”

Syndax Pharmaceuticals Inc: Increased authorized shares from 110,000,000 to 210,000,000, consisting of 200,000,000 common shares and 10,000,000 preferred shares (effective 2023-05-17).

“On May 17, 2023, following receipt of the affirmative vote from the holders of a majority of the outstanding shares of common stock of Syndax Pharmaceuticals, Inc. (the “ Company ”) at the Annual Meeting (as defined below), the Company filed a certificate of amendment to the Company’s amended and restated certificate of incorporation (the “ Certificate Amendment ”) with the Secretary of State of the State of Delaware to increase the authorized number of total shares of all classes of stock that the Company has authority to issue from 110,000,000 shares to 210,000,000 shares, consisting of two classes: (1) 200,000,000 shares of common stock, $0.0001 par value per share, and (2) 10,000,000 shares of preferred stock, $0.001 par value per share. The Certificate Amendment became effective immediately upon filing.”

Syndax Pharmaceuticals Inc shareholders approved Approval of amendment to the Company’s amended and restated certificate of incorporation to increase the number of authorized shares of common stock at the 2023-05-17 meeting.

“Proposal 4 : Approval of amendment to the Company’s amended and restated certificate of incorporation to increase the number of authorized shares of common stock: For Against Abstain Broker Non-Votes 62,460,712 675,568 6,907 —”

Syndax Pharmaceuticals Inc shareholders approved Ratification of selection of independent registered public accounting firm at the 2023-05-17 meeting.

“Proposal 3 : Ratification of selection of independent registered public accounting firm: For Against Abstain Broker Non-Votes 63,037,788 103,402 1,997 —”

Syndax Pharmaceuticals Inc shareholders approved Advisory vote on executive compensation at the 2023-05-17 meeting.

“Proposal 2 : Advisory vote on executive compensation: For Against Abstain Broker Non-Votes 58,132,013 787,719 8,890 4,214,565”

Syndax Pharmaceuticals Inc shareholders approved Election of directors at the 2023-05-17 meeting.

“Proposal 1 : Election of directors: Nominee For Withheld Broker Non-Votes Pierre Legault 35,300,479 23,628,143 4,214,565 Michael A. Metzger 57,418,793 1,509,829 4,214,565”

Syndax Pharmaceuticals Inc reported financial results for the quarter ended March 31, 2023.

“On May 8, 2023, Syndax Pharmaceuticals, Inc. (the " Company ") issued a press release announcing its financial results for the quarter ended March 31, 2023.”

Keith A. Goldan was appointed as Principal Accounting Officer at Syndax Pharmaceuticals Inc.

“The Company has appointed Keith A. Goldan, the Company’s Chief Financial Officer, Treasurer and its Principal Financial Officer, as its Principal Accounting Officer.”

Alexander Nolte resigned as Vice President, Chief Accounting Officer at Syndax Pharmaceuticals Inc.

“Effective May 5, 2023, Alexander Nolte resigned from his positions as the Company’s Vice President, Chief Accounting Officer and its Principal Accounting Officer, in order to pursue another opportunity.”

Briggs W. Morrison resigned as President, Head of Research and Development at Syndax Pharmaceuticals Inc.

“On March 29, 2023, Briggs W. Morrison M.D., President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development.”

Neil Gallagher was appointed as President, Head of Research and Development at Syndax Pharmaceuticals Inc.

“On March 30, 2023, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Neil Gallagher, M.D., Ph.D., will join the Company as President, Head of Research and Development, effective April 10, 2023.”

Syndax Pharmaceuticals Inc reported financial results for the fourth quarter and full year ended December 31, 2022.

“Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.”

Syndax Pharmaceuticals Inc entered into Underwriting Agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC valued at approximately $150.0 million (effective 2022-12-06).

“On December 6, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters (collectively, the “ Underwriters ”), relating to the issuance and sale of 6,818,182 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $22.00 per share (the “ Offering ”).”

Steve Sabus was appointed as Chief Commercial Officer at Syndax Pharmaceuticals Inc.

“On December 2, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Steve Sabus will join the Company as Chief Commercial Officer, effective December 5, 2022.”

Syndax Pharmaceuticals Inc reported financial results for the third quarter ended September 30, 2022.

“On November 3, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2022.”

Keith A. Goldan was appointed as Chief Financial Officer at Syndax Pharmaceuticals Inc.

“On June 13, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Keith A. Goldan will join the Company as Chief Financial Officer, effective June 13, 2022.”

Michael L. Meyers departed as Chief Medical Officer at Syndax Pharmaceuticals Inc.

“Michael L. Meyers, M.D., Ph.D., Chief Medical Officer of the Company, notified the Company of his intention to retire and resign from his position as Chief Medical Officer.”

Kate Madigan was appointed as Chief Medical Officer at Syndax Pharmaceuticals Inc.

“Kate Madigan, M.D. will join the Company as Chief Medical Officer, effective March 1, 2022.”

Fabrice Egros resigned as Director at Syndax Pharmaceuticals Inc.

“On February 22, 2022, Fabrice Egros, PharmD, Ph.D. notified Syndax Pharmaceuticals, Inc. (the "Company") of his decision to resign from the Board of Directors of the Company (the "Board") due to an increase in the scope of his role at Lupin Limited.”

Michael A. Metzger was appointed as Chief Executive Officer at Syndax Pharmaceuticals Inc.

“On the same date, the Board appointed Michael A. Metzger, previously the Company’s President, Chief Operating Officer, and a member of the Board, to serve as the Company’s Chief Executive Officer.”

Briggs W. Morrison, M.D. changed role as President, Head of Research and Development at Syndax Pharmaceuticals Inc.

“On February 2, 2022, Briggs W. Morrison, M.D., transitioned from his role as Chief Executive Officer and principal executive officer of Syndax Pharmaceuticals, Inc. (the “ Company ”) to President, Head of Research and Development of the Company.”